Contemporary Role of Systematic Prostate Biopsies: Indications, Techniques, and Implications for Patient Care

O Ukimura, JA Coleman, A de la Taille, M Emberton, JI Epstein, SJ Freedland, G Giannarini, AS Kibel, R Montironi, G Ploussard, Monique Roobol - Bouts, V Scattoni, JS Jones

Research output: Contribution to journalArticleAcademicpeer-review

199 Citations (Scopus)


Context: Prostate cancer (PCa) screening to detect early stage PCa has resulted in increased identification of small-volume, low-grade PCa, many of which meet criteria for clinically indolent disease. Nevertheless, there remains some degree of underdetection of high-risk PCa in substantial numbers of men despite current diagnostic strategies. Objective: To discuss the contemporary role of prostate biopsy (PB), focusing on the indications, techniques, and limitations of current PB techniques and evolving techniques affecting patient care. Evidence acquisition: A comprehensive Medline search was performed using the medical subject heading search terms prostate cancer, detection, prostate biopsy, significant cancer, and diagnosis, with restriction to the English language. Emphasis was given to publications within the past 5 yr. Evidence synthesis: Because abnormal digital rectal examination (DRE) and prostate-specific antigen (PSA) tests alone lack specificity for cancer, there is no universal indication for PB. This lack has inspired exploration for a cancer-specific biomarker and prediction tools such as risk calculators. Indication for biopsy should involve a balance between the underdiagnosis of high-risk cancers and the potential risks for the overdetection of clinically insignificant cancers as well as biopsy-rel Conclusions: Current data support the utility of extended PB templates for initial TRUS PB intended to detect clinically significant PCa. Repeat PB in the setting of prior negative PB on the grounds of clinical suspicion or for risk-stratified approaches to management of low risk PCa requires balancing overdetection of low-risk cancer with the potential to miss significant cancer. Several options, including modern image-guided targeting, biomarker development, transrectal saturation PB, and 3D t
Original languageUndefined/Unknown
Pages (from-to)214-230
Number of pages17
JournalEuropean Urology
Issue number2
Publication statusPublished - 2013

Research programs

  • EMC MM-03-49-01

Cite this